Development of a predictive model for nafamostat mesylate dosing in hemodialysis.

ABSTRACT:

Background

Nafamostat mesylate, an anticoagulant with a short half-life, is useful during hemodialysis for patients at high risk of bleeding. Research on the appropriate dosage of nafamostat has been insufficient. This study aimed to investigate the optimal dosage of nafamostat using a dosage prediction model.

Methods

We retrospectively analyzed medical records from 12 centers affiliated with Yeolin Medical Foundation over an 8-month period. Candidate predictor variables were evaluated using bootstrapping and stepwise regression to determine feature importance. Predictive models were compared based on performance metrics.

Results

In total, 308 sessions from 88 patients without dialyzer clotting were selected. The average nafamostat dose was 21.90 ± 6.82 mg/h. The top

SUBMITTER: Lee SY 

PROVIDER: S-EPMC12533325 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature